Beyond Air Shares Climb Nearly 9% After Product Gets FDA Approval
June 29 2022 - 1:25PM
Dow Jones News
By Michael Dabaie
Beyond Air Inc. shares were up 8.7% to $6.29 after getting FDA
approval for its LungFit PH product in neonates with hypoxic
respiratory failure.
The company focused on developing inhaled nitric oxide for
treatment of patients with respiratory conditions, after the bell
Tuesday said the U.S. Food and Drug Administration approved LungFit
PH to treat term and near-term neonates with hypoxic respiratory
failure. Hypoxic respiratory failure is often referred to as
persistent pulmonary hypertension of the newborn.
LungFit PH is the initial device from the LungFit therapeutic
platform of nitric oxide generators that use Ionizer technology and
is the first FDA-approved product for Beyond Air.
Truist analyst Gregory D. Fraser said the LungFit PH has the
potential to be disruptive in the $400 million nitric oxide market
and raised its price target to $20 from $16 on the approval. "We
see significant upside for the stock as XAIR executes on the
LungFit PH launch and advances its pipeline, and are reiterating
our Buy rating," the analyst said.
Oppenheimer analysts in a research note reiterated shares at
Outperform.
Given hospital demonstration and contracting time, the
Oppenheimer analysts said they view fiscal fourth-quarter 2023, the
March 2023 quarter, as the first benchmark quarter of revenue.
"We believe [inhaled nitric oxide] has compelling benefits over
existing cylinder technology (safety, convenience, size) and that
XAIR's technology has multiple important applications," the note
said.
"Due to the many advantages of the LungFit PH system, we have no
plans to compete on price," Beyond Air Chief Commercial Officer
Duncan Fatkin said in a conference call. Since removing cylinders
leads potential workflow and logistical benefits, "there is a
strong healthcare economic argument that even a higher price will
still lead to reduction in the overall costs of delivering nitric
oxide for hospitals," Mr. Fatkin said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 29, 2022 13:10 ET (17:10 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.